by Stacey Hawkins | Feb 10, 2020 | Immunotherapies
The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—Kymriah (Novartis; Basel, Switzerland) and Yescarta—(Gilead; Foster City, CA) were approved in 2017, and remain one of the hottest immunotherapies on the market today. They work by... 
by Stacey Hawkins | Mar 19, 2015 | Uncategorized
HBO shines light on novel immunotherapies HBO’s Vice news program selected a few promising technologies from the immunotherapy pipeline to feature in its Killing Cancer episode. Vice’s heartrending human interest stories illustrated the potential of three...
